Edition:
United Kingdom

CASI Pharmaceuticals Inc (CASI.OQ)

CASI.OQ on NASDAQ Stock Exchange Capital Market

6.90USD
7:02pm BST
Change (% chg)

$0.18 (+2.68%)
Prev Close
$6.72
Open
$6.67
Day's High
$7.06
Day's Low
$6.67
Volume
45,620
Avg. Vol
143,519
52-wk High
$8.40
52-wk Low
$0.91

Latest Key Developments (Source: Significant Developments)

CASI Pharmaceuticals Reports Q1 Loss Per Share Of $0.05
Tuesday, 15 May 2018 

May 15 (Reuters) - CASI Pharmaceuticals Inc ::CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL AND BUSINESS RESULTS.Q1 LOSS PER SHARE $0.05.  Full Article

CASI Pharmaceuticals Q4 Loss Per Share $0.08
Thursday, 29 Mar 2018 

March 29 (Reuters) - CASI Pharmaceuticals Inc ::CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.08.AS OF DECEMBER 31, 2017, CASI HAD CASH AND CASH EQUIVALENTS OF APPROXIMATELY $43.5 MILLION.  Full Article

Casi Pharmaceuticals Files For Stock Shelf Of Upto $100 Million
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Casi Pharmaceuticals Inc ::CASI PHARMACEUTICALS INC FILES FOR STOCK SHELF OF UPTO $100 MILLION - SEC FILING.  Full Article

Casi pharmaceuticals Q3 loss per share $0.03
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Casi Pharmaceuticals Inc :Casi Pharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $0.03.As of September 30, 2017, Casi had cash and cash equivalents of approximately $21.6 million​.  Full Article

Casi Pharmaceuticals Q2 loss per share $0.08
Monday, 15 Aug 2016 

Casi Pharmaceuticals Inc : Casi Pharmaceuticals reports second quarter 2016 financial results .Q2 loss per share $0.08.  Full Article

BRIEF-CASI Pharma Says Advisory Committee to Review Evomela Between April 25-26

* CASI PHARMACEUTICALS - RECEIPT OF LETTER FROM CENTER FOR DRUG EVALUATION FOR INJECTION SCHEDULED FOR REVIEW BY ADVISORY COMMITTEE